| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/24/2001 | CN1281433A Hydroxamic acid derivatives as matrix metalloprotease (MMP) inhibitors |
| 01/24/2001 | CN1281429A Novel aryloxy-alkyl-dialkylamines |
| 01/24/2001 | CN1281373A Pharmaceutical compositions containing cyclodextrins and taxoids |
| 01/24/2001 | CN1281371A Method for obtaining vaccines for preventing pathogenic effects related to retroviral infection |
| 01/24/2001 | CN1281336A Treatment of neoplasms with viruses |
| 01/24/2001 | CN1280855A Medicinal composition containing algal protein polyose extract and extraction of algal protein polyose |
| 01/24/2001 | CN1280852A Xiaoaiyishen decoction |
| 01/24/2001 | CN1280850A Medicine for treating cancer |
| 01/24/2001 | CN1280845A Medicine containing ginsenoside Rh1 and its new application |
| 01/24/2001 | CN1280826A Application of malaridine in preparing antitumor medicine and tumor tolerance-reversing medicine |
| 01/24/2001 | CN1061047C Process of preparing etoposide phosphate |
| 01/24/2001 | CN1061042C Adhesion receptor antagonists |
| 01/24/2001 | CN1060941C Process for preparation of active anticancer Chinese herbal medicine |
| 01/24/2001 | CN1060935C Preparation method of arsenical capable of applying to cancer focus |
| 01/24/2001 | CN1060933C Application of googerotin used as antineoplastic medicine |
| 01/23/2001 | US6177568 Intermediates for the synthesis of camptothecin derivatives |
| 01/23/2001 | US6177561 Preparation of acid amides and metallization of compounds |
| 01/23/2001 | US6177551 Bridged aromatic substituted amine ligands with donor atoms |
| 01/23/2001 | US6177550 Process for extraction of a growth factor complex |
| 01/23/2001 | US6177546 Human glutathione-S-transferase |
| 01/23/2001 | US6177545 Antibody which preferentially binds an epitope of an enzymatic protein; for diagnosis of time events in tumor propagation and metastasis, autoimmune diseases, kidney defects and atherosclerotic injury |
| 01/23/2001 | US6177470 Prostaglandin synthesis |
| 01/23/2001 | US6177439 Anticarcinogenic agents; viricides |
| 01/23/2001 | US6177432 Farnesyltransferase inhibiting quinazolinones |
| 01/23/2001 | US6177419 Antioxidant chelate compounds for preventing oxygen free radical-associated diseases in mammals; neuroprotectants, superoxide dismutase (sod), catalase (cat) and/or peroxidase (pod) mimetics |
| 01/23/2001 | US6177408 Compounds such as 3-(1-methyl-4(1-methyl-4(1-methyl-4(4-n,n-bis(2 -chloroethyl)aminocinnamoylamido)pyrrole-2-carboxamido)pyrrole-2 -carboxamido)pyrrole-2-carboxamido)propionamidine |
| 01/23/2001 | US6177401 Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| 01/23/2001 | US6177273 Antisense modulation of integrin-linked kinase expression |
| 01/23/2001 | US6177122 Cancer chemoprotective food products |
| 01/23/2001 | US6177078 Binding interleukins |
| 01/23/2001 | US6177076 Method of treating bladder cancer with wild type vaccinia virus |
| 01/23/2001 | CA2296884C Targeted liposomes and methods for liposome-protein coupling |
| 01/23/2001 | CA2191790C Biaromatic compounds containing an adamantyl group in para position; pharmaceutical and cosmetic compositions containing them and use thereof |
| 01/22/2001 | CA2312203A1 Cyclobutene derivatives, their preparation and their therapeutic uses |
| 01/18/2001 | WO2001004629A1 E4orf4 and pp2a polypeptides, modulators, and mimetics for selectively inducing cell death |
| 01/18/2001 | WO2001004341A1 Method for producing oligopolysaccharides |
| 01/18/2001 | WO2001004329A1 Modified human granulocyte-colony stimulating factor and process for producing same |
| 01/18/2001 | WO2001004326A1 Tankyrase homolog protein (thp), nucleic acids, and methods related to the same |
| 01/18/2001 | WO2001004318A2 Myxoma virus genes for immune modulation |
| 01/18/2001 | WO2001004313A1 Methods and compositions for preventing the formation of aberrant rna during transcription of a plasmid sequence |
| 01/18/2001 | WO2001004309A1 T-CELL RECEPTOR η ALTERNATE READING FRAME PROTEIN, (TARP) AND USES THEREOF |
| 01/18/2001 | WO2001004308A1 Human lim domain proteins |
| 01/18/2001 | WO2001004305A2 Human proteins involved in detoxification |
| 01/18/2001 | WO2001004303A1 Compositions corresponding to a calcium transporter and methods of making and using same |
| 01/18/2001 | WO2001004297A2 Human proteins having hydrophobic domains and dnas encoding these proteins |
| 01/18/2001 | WO2001004290A1 Triplex-forming oligonucleotides and their use in therapy |
| 01/18/2001 | WO2001004282A2 Replication-competent anti-cancer vectors |
| 01/18/2001 | WO2001004266A1 A lung cancer associated retrovirus, gene delivery vector and methods of use thereof |
| 01/18/2001 | WO2001004160A1 Anti-idiotypic antibodies of fibroblast growth factors and their use as medicines |
| 01/18/2001 | WO2001004157A2 NOVEL METHOD AND COMPOSITION FOR INHIBITION OF ANGIOGENESIS USING ANTAGONISTS BASED ON MMP-9 AND β1 INTEGRINS |
| 01/18/2001 | WO2001004155A2 Feline interleukin-12 as an immune stimulant |
| 01/18/2001 | WO2001004140A1 Compounds for treatment of infectious and immune system disorders and methods for their use |
| 01/18/2001 | WO2001004130A1 Phosphoramide compounds |
| 01/18/2001 | WO2001004125A1 Staurosporin derivatives |
| 01/18/2001 | WO2001004111A1 Anilinoquinazolines as protein tyrosine kinase inhibitors |
| 01/18/2001 | WO2001004108A1 Amino ceramide-like compounds and therapeutic methods of use |
| 01/18/2001 | WO2001004103A1 Benzazepinones and quinazolines |
| 01/18/2001 | WO2001004099A1 Benzoylpyridazines |
| 01/18/2001 | WO2001004089A1 Vitamin d3 analogs |
| 01/18/2001 | WO2001003743A1 Manipulation of tissue or organ type using the notch pathway |
| 01/18/2001 | WO2001003737A1 Immunoglobulin fusion proteins |
| 01/18/2001 | WO2001003720A2 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 01/18/2001 | WO2001003717A2 Methods of inducing cell death |
| 01/18/2001 | WO2001003716A1 Method of treating malignancies and viral infections and improving immune function with a dietary supplement |
| 01/18/2001 | WO2001003699A1 Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances |
| 01/18/2001 | WO2001003696A1 Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |
| 01/18/2001 | WO2001003688A2 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
| 01/18/2001 | WO2001003667A1 Delivery system for biological material |
| 01/18/2001 | WO2000063378A3 Zalpha13: a human secreted protein |
| 01/18/2001 | WO2000055180A3 Human lung cancer associated gene sequences and polypeptides |
| 01/18/2001 | WO2000047215A3 Methods for anti-tumor therapy |
| 01/18/2001 | WO2000037067A3 Sensitizing agents for the treatment of skin lesions |
| 01/18/2001 | WO2000035492A3 Vitronectin receptor antagonist pharmaceuticals |
| 01/18/2001 | WO2000034245A3 Crystalline form of benzoquinoline-3-one derivatve as inhibitor of 5-alpha reductase |
| 01/18/2001 | WO2000031092A3 Benzyllactobionamides as inhibitors of smooth muscle cell proliferation |
| 01/18/2001 | WO2000024360A8 Preparation and use of solidified oils |
| 01/18/2001 | WO2000023565B1 Novel neuropilin/growth factor binding and uses thereof |
| 01/18/2001 | WO1999050403A3 Method and reagents for the treatment of diseases or conditions related to molecules involved in angiogenic responses |
| 01/18/2001 | DE19934088A1 Neue C-19-halogensubstituierte Steroide der Androst-9(11)-en-Reihe, Verfahren zu ihrer Herstellung sowie ihre Verwendung New C-19 halogen-substituted steroids of androst-9 (11) -en-series, processes for their preparation and their use |
| 01/18/2001 | DE19933173A1 Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶ Cyclic peptide derivatives as inhibitors of the integrin alpha¶v¶beta¶6¶ |
| 01/18/2001 | DE19932796A1 Diacylhydrazinderivate Diacylhydrazinderivate |
| 01/18/2001 | DE19932555A1 Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen Drugs with a protective effect against oxidative-toxic and in particular against cardiotoxic substances |
| 01/18/2001 | CA2383496A1 Compounds for treatment of infectious and immune system disorders and methods for their use |
| 01/18/2001 | CA2379373A1 Novel method and composition for inhibition of angiogenesis using antagonists based on mmp-9 and .beta.1 integrins |
| 01/18/2001 | CA2379345A1 T-cell receptor .gamma. alternate reading frame protein, (tarp) and uses thereof |
| 01/18/2001 | CA2379133A1 Human proteins involved in detoxification |
| 01/18/2001 | CA2379035A1 Staurosporin derivatives |
| 01/18/2001 | CA2379010A1 Methods of inducing cell death |
| 01/18/2001 | CA2378989A1 Human lim domain proteins |
| 01/18/2001 | CA2378653A1 Methods and compositions for preventing the formation of aberrant rna during transcription of a plasmid sequence |
| 01/18/2001 | CA2378600A1 Amino ceramide-like compounds and therapeutic methods of use |
| 01/18/2001 | CA2378595A1 Benzoylpyridazines |
| 01/18/2001 | CA2378567A1 Novel myxoma genes for immune modulation |
| 01/18/2001 | CA2378562A1 Method for producing oligopolysaccharides |
| 01/18/2001 | CA2378515A1 Compositions corresponding to a calcium transporter and methods of making and using same |
| 01/18/2001 | CA2378465A1 Manipulation of tissue or organ type using the notch pathway |
| 01/18/2001 | CA2378451A1 Anti-idiotypic antibodies of fibroblast growth factors and their use as medicines |
| 01/18/2001 | CA2378402A1 Method of treating malignancies and viral infections and improving immune function with a dietary supplement |
| 01/18/2001 | CA2378179A1 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 01/18/2001 | CA2377502A1 Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |